
Astrazeneca's Savings Plan Starts Cutting US Sales Jobs
AstraZeneca is trimming its US sales force as the cost-cutting program it unveiled on October 30 begins to bite. The drugmaker, whose stock ($AZN) jumped more than 4% that day, targeted $1.5 billion in annual savings funded by up to $2 billion in one-off restructuring charges running through 2029. Back then the company only said restructuring "could mean job cuts" without confirming any; two weeks later those cuts are landing in the commercial unit that drove $16.2 billion in quarterly revenue.